文献速递消化道肿瘤放疗姑息放疗与转移瘤

PD-1抑制剂联合同步根治性放疗及免疫营养支持治疗食管鳞癌的II期多中心临床试验

Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial.
PubMed 文献 · Radiat Oncol · 2025-04-18

本研究为II期单臂多中心临床试验,评估PD-1抑制剂(信迪利单抗)联合根治性放疗及免疫营养支持用于PD-L1阳性、无法耐受同步放化疗的不可切除非转移性食管鳞癌患者的疗效与安全性。主要终点为1年无进展生存率,次要终点包括客观缓解率、总生存期及不良事件发生率。

要点

  • 入组人群为PD-L1阳性、不可切除、非转移性且无法耐受同步放化疗的食管鳞癌患者。
  • 方案为放疗总剂量50-60 Gy分25-30次,信迪利单抗200 mg每三周一次,联合肠内营养乳剂600-1600 ml/天。
  • 主要终点为1年无进展生存率,次要终点包括客观缓解率、总生存期和不良事件发生率。

核心结论

  • 本研究旨在评估一种毒性较低的免疫治疗、放疗与营养支持联合方案能否改善无法耐受传统治疗的不可手术食管鳞癌患者的生存率和生活质量。
  • 研究还将探索免疫营养支持与PD-1抑制剂的协同效应。

研究设计与样本

  • II期单臂多中心临床试验,入组组织学确诊的不可切除食管鳞癌、PD-L1阳性且不适合同步放化疗的患者。
  • 放疗总剂量50-60 Gy分25-30次,信迪利单抗200 mg每三周一次,补充肠内营养乳剂600-1600 ml/天。
  • 主要终点为1年无进展生存率,次要终点包括客观缓解率、总生存期及不良事件发生率。
  • 试验注册号NCT06342167。

关键数值与推荐

  • 放疗总剂量50-60 Gy分25-30次。
  • 信迪利单抗200 mg每三周一次。
  • 肠内营养乳剂600-1600 ml/天。
  • 主要终点为1年无进展生存率。

临床怎么用

  • 针对PD-L1阳性、不可切除非转移性且无法耐受同步放化疗的食管鳞癌患者,本试验评估PD-1抑制剂联合根治性放疗及免疫营养支持这一替代治疗路径。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Esophageal cancer is one of the most common malignant tumors, with China accounting for 50% of the world's total incidence. Concurrent chemoradiotherapy (cCRT) with platin-based dual-drug regimen is the standard treatment for inoperable, locally advanced esophageal cancer in patients with a good performance status. However, certain patients possess risk factors that heighten toxicity and reduce their tolerance to cCRT, thereby challenging the feasibility of standard treatment. This study evaluates an alternative therapeutic approach combining programmed cell death protein 1 inhibitor (PD-1 inhibitor), definitive radiotherapy, and immunonutrition support for patients with unresectable non-metastatic esophageal cancer expressing PD-L1 who are intolerant to cCRT. METHODS: This is a phase II, single-arm, multicenter clinical trial involving patients with histologically confirmed unresectable esophageal squamous cell carcinoma (ESCC), who exhibit positive PD-L1 and are unsuitable for cCRT. Participants will receive a total radiotherapy dose of 50-60 Gy in 25-30 fractions, sintilimab (200 mg every three weeks), alongside, supplemented by enteral nutritional emulsion (600-1600 ml/day). The primary endpoint is the 1-year progression-free survival rate, with secondary endpoints including objective response rate, overall survival and incidence of adverse events. CONCLUSION: This research has the potential to redefine treatment for inoperable ESCC patients who cannot tolerate conventional therapies. By evaluating a less toxic regimen that combines immunotherapy, radiotherapy, and nutritional support, we aim to determine if this approach can improve both survival rates and quality of life. The synergistic effects of immunonutrition support and PD-1 inhibitor will also be explored. TRIAL REGISTRATION: NCT06342167.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Luo S, Wang X, et al. Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial. Radiat Oncol. 2025. PMID: 40251674. doi:10.1186/s13014-025-02604-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。